
Healthcare & Pharmaceuticals · BSE
Incorporated in 2012, Ahmedabad-based Earum Pharmaceuticals Limited is engaged in the trading, marketing, and distribution of pharmaceutical formulation products, with a portfolio of around 125 formulations including multivitamins, gynaecology drugs, steroids, antibiotics, cerebral activators, and gastrointestinal medicines. The company is also involved in trading active pharmaceutical ingredients such as Amoxicillin Trihydrate IP, Levofloxacin Hemihydrate IP, and Albendazole IP, and operates through two main business models—marketing its own branded formulations and trading generic formulations of other brands, with about 24 products manufactured by third parties and sold under its own brand. Earum Pharmaceuticals operates a well-equipped warehouse in Ahmedabad, Gujarat, and has a presence in both domestic and international markets including South East Asia, Latin America, and Africa, while focusing on expanding its global footprint, improving market capabilities, and maintaining high-quality product standards.
Price Band
₹36
Issue Size
₹7.00 Cr
Lot Size
3000 shares
GMP
Est. Listing
₹36
at current GMP
Subscribed
—
Open
21 Jun 2019
Close
26 Jun 2019
Allotment
1 Jul 2019
Refund
2 Jul 2019
Demat Credit
3 Jul 2019
Listing
4 Jul 2019
Last updated: 19 Oct 2026
Current Premium
Issue Price (Upper)
₹36
Band: ₹36
Estimated Listing Price
₹36
Upper price + GMP
Lot Size
3000 shares
Min investment ₹1,08,000
Estimated Profit / Lot
₹0
3000 × ₹0
Grey Market Premium trend
—
▲ 0 today
Updated less than a minute ago
| Date | GMP (₹) | GMP % | Est. Listing |
|---|---|---|---|
| 31 Oct 2026 | — | 0.0% | ₹36 |
| 30 Oct 2026 | — | 0.0% | ₹36 |
| 29 Oct 2026 | — | 0.0% | ₹36 |
GMP is unofficial market data. Not a guarantee of listing performance.
Earum Pharmaceuticals Limited is bringing an initial public offering (IPO) in the Healthcare & Pharmaceuticals sector with an aggregate issue size of ₹7 Crores. The shares are offered at a price band of ₹36 to ₹36 per equity share on BSE. Currently, grey market participants and retail investors are watching the bidding trend, premium movement, and anchor book demand with keen interest.
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 3000 shares (approx. ₹1,08,000 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment reconciliation will be managed by Bigshare Services Private Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2019-07-03, while un-allotted funds or UPI block mandates will be released on 2019-07-02.
The latest grey market premium for Earum Pharmaceuticals Limited IPO is ₹0, which indicates an expected listing price of ₹36.
Kostak rate is the profit amount an investor earns by selling their entire IPO application in the grey market before allotment is finalized.
No. GMP is an unofficial indicator discovered between dealers outside of SEBI-regulated exchanges. Actual listing price is determined by demand-supply discovery on NSE/BSE during the pre-open auction.